The new sparkling DIME (Digi MarketEr) are the ones who embrace digital transformation with open arms and voraciously feed on data analytics to satisfy their performance outcomes with an informed business decision. The benefit of being DIME is that it propels data management out of the hands of individual stakeholders, and puts data sets with insights on to center glass table (Transparent workplace) for informed decision making.

The pill is now a commodity that many of these companies provide at heavy discounts, making money off everything ‘beyond the pill’. Investors are betting heavily on the potential of technological innovation to transform the way healthcare is delivered. The Economic Times reported that in 2021, India recorded investments of $77 billion across 1,266 deals including 164 large deals worth $58 billion. While the money reduced in 2022, the reason wasn’t a lack of faith in this business model. Meanwhile, the pharmaceuticals industry that is most affected by this quiet but rapid change, is grappling with its entrenched culture. Its current business is so profitable that everything else pales in comparison. ‘Build, measure, learn, build again’ – a mantra of the health tech industry is alien to pharma that doesn’t learn, build or measure after launching a product. Pharma also thinks of its customers as doctors alone and does precious little to connect with patients, or caregivers. People who are not sick do not feature on their radar at all. These are cultural values that keep pharma focused on the pill and discourage thinking beyond it. A social media poll conducted by MedicinMan showed almost predictable responses. 100+ respondents who work in the pharma industry in India were quite clearly divided. 48% of them wanted to know what beyond the pill actually meant, while 23% wanted to know how to execute it. The rest felt that the ultra-competitive environment in the Indian generics market required very high share-of-voice tactics (19%), or that their customers demanded product information (9%).

MVS Murthy I began my career as a Medical Rep...

1. From Gut Hormone to “Wonder Drug” If you strip...

It is the twentieth anniversary of the new patent act in January 2025. The post-patent (P20) era is a story of resilience, determination, and charting a course that set global ambitions, a story of finding opportunity in adversity. It is a story for case studies in business schools, in international studies, in global health efforts.

A recent industry spotlight by Venkat Mutavi notes a...

India's pharmaceutical market charged into 2026 with strong momentum,...

Today's Brand Equity cover — a woman lost in...

Walk into almost any clinic today and you will...

“Lifestyle advice often asks patients to fight powerful evolutionary...

A recent industry spotlight by Venkat Mutavi notes a...

India's pharmaceutical market charged into 2026 with strong momentum,...

Today's Brand Equity cover — a woman lost in...

Walk into almost any clinic today and you will...

“Lifestyle advice often asks patients to fight powerful evolutionary...

A recent industry spotlight by Venkat Mutavi notes a...

India's pharmaceutical market charged into 2026 with strong momentum,...

Today's Brand Equity cover — a woman lost in...

Walk into almost any clinic today and you will...

“Lifestyle advice often asks patients to fight powerful evolutionary...

A recent industry spotlight by Venkat Mutavi notes a...

India's pharmaceutical market charged into 2026 with strong momentum,...

Today's Brand Equity cover — a woman lost in...

Walk into almost any clinic today and you will...

“Lifestyle advice often asks patients to fight powerful evolutionary...